Deep Vein Thrombosis
Conditions
Interventions
High-risk with individualized-dose enoxaparin group:100 anti-Xa IU/kg (equivalent to 1 mg/kg) subcutaneously every 12 hours.
High-risk with fixed-dose enoxaparin:4000 anti-Xa IU (40 mg) subcutaneously once daily
Low-risk group received fixed-dose enoxaparin:4000 anti-Xa IU (40 mg) subcutaneously once daily
Sponsors
Sun Yat-sen memorial hospital, Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
22 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 22 to 80 years, undergoing their first unilateral joint replacement surgery; 2. Normal coagulation function before surgery; 3. No lower limb vascular disease or venous thrombosis before surgery; 4. Normal liver and kidney function or Child-Pugh class A; 5. No contraindications to anticoagulant drugs; 6. Agree to participate in this study and sign the informed consent form
Exclusion criteria
Exclusion criteria: 1. Patients with severe cardiopulmonary diseases, cardiovascular embolism, severe tumors, infections, or active tuberculosis; 2. Patients with contraindications to anticoagulation, abnormal liver function (Child-Pugh class B or C), or end-stage renal disease (glomerular filtration rate <15 ml/min); 3. Patients allergic to enoxaparin sodium or with coagulation disorders; 4. Patients receiving anticoagulant therapy for other diseases; 5. Patients diagnosed with lower limb deep vein thrombosis before surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Deep vein thrombosis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pulmonary embolism;Postthrombotic syndrome; | — |
Countries
China
Contacts
Public ContactJie Xu
Sun Yat-sen memorial hospital, Sun Yat-sen University
Outcome results
None listed